WO2021224942A1 - Polymorphic forms of amlodipine benzoate and process for the preparation thereof - Google Patents

Polymorphic forms of amlodipine benzoate and process for the preparation thereof Download PDF

Info

Publication number
WO2021224942A1
WO2021224942A1 PCT/IN2021/050433 IN2021050433W WO2021224942A1 WO 2021224942 A1 WO2021224942 A1 WO 2021224942A1 IN 2021050433 W IN2021050433 W IN 2021050433W WO 2021224942 A1 WO2021224942 A1 WO 2021224942A1
Authority
WO
WIPO (PCT)
Prior art keywords
amlodipine
amlodipine benzoate
crystalline
benzoate
xrpd
Prior art date
Application number
PCT/IN2021/050433
Other languages
French (fr)
Inventor
Daniel Levin
Jayprakash PARIHAR
Prashant Pawar
Pramod CHAUDHARI
Jamankumar MANDAVIYA
Dattatray SHEJUL
Sitasharan RAY
Original Assignee
Alkem Laboratories Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkem Laboratories Ltd. filed Critical Alkem Laboratories Ltd.
Publication of WO2021224942A1 publication Critical patent/WO2021224942A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/04Monocyclic monocarboxylic acids
    • C07C63/06Benzoic acid
    • C07C63/08Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Definitions

  • the present invention relates to the polymorphic forms of Amlodipine benzoate and pharmaceutical compositions thereof.
  • the present invention also relates to the processes for the preparation of Amlodipine benzoate.
  • the present invention further relates to the manufacturing processes for the preparation of crystalline Amlodipine benzoate.
  • Amlodipine benzoate chemically known as 3-Ethyl-5-methyl ( ⁇ )-2-[(2- aminoethoxy)methyl]-4-(2-chlorophenyl)-l,4-dihydro-6-methyl-3,5- pyridinedicarboxylate benzenecarboxylate is benzoate salt of Amlodipine and is represented by the formula I.
  • Amlodipine benzoate is the active ingredient of the drug Katerzia® and intended for oral suspension. Amlodipine benzoate is a calcium channel blocker and is intended for the treatment of hypertension by reducing the blood pressure and thus reducing the risk of various cardiovascular events.
  • Prior to Katrezia® W02005/089353 generically disclosed (S)- Amlodipine benzoate as the first intermediate salt during the preparation of (S)-Amlodipine maleate.
  • the PCT doesn’t disclose specific preparation or isolation of (S)-Amlodipine benzoate.
  • CN110372575 discloses eutectic crystal of dihydropyridine calcium antagonist.
  • the disclosed eutectic crystal has molecular formula: (C 20 H 25 CIN 2 O 5 ) (CeHsCOOH) (Y) n , wherein Y is any one of water molecule, ethanol molecule or isopropanol molecule, 0 ⁇ n ⁇ 3, C 20 H 25 CIN 2 O 5 is levamlodipine, C 6 H 5 COOH is benzoic acid.
  • WO20 18/067959 relates to the oral liquid formulation of Amlodipine benzoate, wherein the process for the preparation of oral liquid formulation comprises formation of Amlodipine benzoate in situ by reaction of more aqueous soluble Amlodipine salt (Amlodipine besylate or other Amlodipine salts) than Amlodipine benzoate, with a molar excess of sodium benzoate in the presence of at least one additional excipient.
  • a particular polymorphic form of a compound may have certain physical properties that differ from those of any other crystalline or amorphous forms and such properties may influence markedly the chemical and pharmaceutical processing of compound, particularly when the compound is prepared or used on a commercial scale.
  • each crystal form of a compound may show differences in physical properties such as crystalline size and shape, melting point, density, hygroscopicity, solubility, suspending properties and stability.
  • the more stable crystalline form is more suitable for formulation and processing on a commercial scale.
  • Amlodipine and its various pharmaceutically acceptable salts have been studied since decades. US4572909 disclosed Amlodipine and pharmaceutically acceptable salts such as, hydrochloride, hydrobromide, sulphate, phosphate or acid phosphate, acetate, maleate, fumarate, lactate, tartrate, citrate and gluconate salts.
  • US4879303 & US6846931 disclosed Amlodipine besylate and Amlodipine pyroglutamate, respectively. Further, there are several prior-arts disclosing preparation of these salts, wherein the process comprises conversion of protected Amlodipine to Amlodipine free base followed by its conversion to desired salt. Particularly, US20020143046, W02005023769, CN102659673, CN105732482, CN103006648 and CN107445889 discloses conversion of Phthaloyl Amlodipine to Amlodipine free base followed by its conversion to desired salt, preferably in situ (without free base isolation).
  • Phthaloyl amlodipine is preferably treated with aqueous solutions of primary amines in water immiscible solvents followed by treatment of the organic phase with suitable organic acids to give amlodipine in the form of a pharmaceutically acceptable salt.
  • Scheme-1 Generic representation of conversion of Phthaloyl Amlodipine to Amlodipine Salt can be depicted as Scheme-1:
  • W02019/200143 discloses a process for conversion of Amlodipine salt (preferably besylate) having more aqueous solubility to Amlodipine benzoate in the presence of sodium benzoate by ultrasonic agitation.
  • the process disclosed therein has one or more issues while scaling up, particularly ultrasonic agitation step.
  • the process comprise conversion of the first Amlodipine salt to final Amlodipine benzoate.
  • the overall Amlodipine benzoate manufacturing process comprises an additional step of isolating the first Amlodipine salt.
  • the inventors of the present invention have developed novel Amlodipine benzoate crystalline forms, possessing desirable processing properties.
  • the inventors of the present invention have addressed the need of developing an industrial viable process for the preparation of Amlodipine benzoate which can overcome the drawbacks associated with the known processes and result in the desired polymorph of Amlodipine benzoate with substantial purity and yield.
  • the primary objective of the present invention is to provide novel polymorphic forms of Amlodipine benzoate and pharmaceutical compositions thereof. Another objective of the present invention is to provide an industrial viable process for the synthesis of Amlodipine benzoate.
  • Another objective of the present invention is to provide a process for the preparation of novel polymorphic forms of Amlodipine benzoate.
  • the present invention provides a crystalline hydrate of Amlodipine benzoate.
  • the present invention provides a crystalline dihydrate Form-I of Amlodipine benzoate characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at about 4.9, 10.7 and 13.7 ⁇ 0.2° 2Q.
  • XRPD X-ray powder diffraction
  • the present invention provides a process for preparing crystalline hydrate Form-I of Amlodipine benzoate, comprising: a. contacting phthaloyl amlodipine with monomethyl amine in methyl tert-butyl ether to obtain Amlodipine free base; b. contacting Amlodipine free base with benzoic acid in methyl tert-butyl ether; and c. isolating crystalline hydrate Form-I of Amlodipine benzoate.
  • the present invention provides a process for preparing crystalline hydrate Form-I of Amlodipine benzoate, comprising: a.
  • the present invention provides crystalline anhydrous form of Amlodipine benzoate.
  • the present invention provides a crystalline Form-II of Amlodipine benzoate characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at about 4.4, 6.0 and 12.1 ⁇ 0.2° 2Q.
  • XRPD X-ray powder diffraction
  • the present invention provides a process for preparing crystalline Form-II of Amlodipine benzoate, comprising: a. contacting phthaloyl amlodipine with monomethyl amine in methyl tert-butyl ether to obtain Amlodipine free base; b. removing water from the organic layer; c. contacting Amlodipine free base with benzoic acid in methyl tert-butyl ether; and d. isolating crystalline Form-II of Amlodipine benzoate.
  • the present invention provides a crystalline Form-Ill of Amlodipine benzoate characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at about 4.1 and 5.6 ⁇ 0.2° 2Q.
  • XRPD X-ray powder diffraction
  • the present invention provides a process for preparing crystalline Form-Ill of Amlodipine benzoate, comprising: a. contacting phthaloyl amlodipine with monomethyl amine in a solvent, selected from the group comprising of hydrocarbon solvents, halogenated solvents or mixture thereof to obtain Amlodipine free base; b. contacting Amlodipine free base with benzoic acid in a solvent, selected from the group comprising of hydrocarbon solvents, halogenated solvents or mixture thereof; and c. isolating crystalline Form-Ill of Amlodipine benzoate.
  • the present invention provides a crystalline monohydrate Form-IV of Amlodipine benzoate characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at about 6.71 and 7.93 ⁇ 0.2° 2Q.
  • XRPD X-ray powder diffraction
  • the present invention provides a process for preparing crystalline monohydrate Form-IV of Amlodipine benzoate, comprising: a. contacting phthaloyl amlodipine with monomethyl amine to obtain amlodipine free base; b. contacting Amlodipine free base with benzoic acid in a Ethyl acetate; and c. isolating crystalline monohydrate Form-IV of Amlodipine benzoate.
  • the present invention provides a process for preparing Amlodipine benzoate, comprising: a. contacting phthaloyl amlodipine with monomethyl amine in a solvent to obtain Amlodipine free base; b. contacting Amlodipine free base with benzoic acid in a solvent; and c. isolating Amlodipine benzoate.
  • the present invention provides an amorphous Amlodipine benzoate.
  • the present invention provides a pharmaceutical composition containing a hydrate, crystalline form or amorphous form of Amlodipine benzoate.
  • ambient temperature refers to a temperature ranging from about 15°C to 35°C, preferably the ambient temperature refers to a temperature from about 20°C to 30°C, more preferably to a temperature of 25°C.
  • hydrate refers to the crystalline solid adducts containing either stoichiometric or nonstoichiometric amounts of water incorporated within the crystal structure. Hydrates can be defined based on the moles of water incorporated within the crystal structure one mole of Amlodipine benzoate. “Monohydrate” stands for one mole of water with respect to one mole of Amlodipine benzoate; “dihydrate” stands for two moles of water with respect to one mole of Amlodipine benzoate; and similarly “hemihydrate” and “sesquihydrate” stands for half and 1.5 moles of water with respect to one mole of Amlodipine benzoate. The same can be indicated as percentage (%) weight of water with respect to weight of Amlodipine benzoate. The percentage (%) weight of water can be obtained by various analytical tools; preferably, Karl-Fischer titration and Thermal Gravimetric Analysis.
  • anhydrous refers to the crystalline or amorphous solid adducts containing undetectable bound water, incorporated within the crystal structure.
  • the term “remove water” or “removing water” stands for removing or separating trace amount of water from a mixture of organic solution with water by the means of distillation, physical adsorption or chemical methods.
  • azeotropically or “azeotropic distillation” stands for the process to break azeotrope and to separate two close-boiling components, facilitated by dean-stark apparatus.
  • contacting includes mixing, adding, slurrying, stirring or a combination thereof.
  • the term “about” are to be construed as modifying a term or value such that it is not an absolute. Such terms will be defined by the circumstances. This includes, at the very least, the degree of expected experimental error, technique error and instrument error for a given technique used to measure a value.
  • XRPD X-ray powder diffraction
  • TGA thermogram endothermic / exothermic peak positions TGA thermogram endothermic / exothermic peak positions
  • typical peak position and intensity variability are taken into account.
  • the peak position (2 theta) will show some inter-apparatus variability, typically as much as 0.2°.
  • relative peak intensities will show inter-apparatus variability as well as variability due to degree of crystallinity, preferred orientation, prepared sample surface and other factors known to those skilled in the art and should be taken as quantitative measure only.
  • Fig. 1 represents an X-ray powder diffraction (XRPD) pattern of the crystalline hydrate Form-I of Amlodipine benzoate prepared as per Example 1;
  • Fig. 2 represents a thermal gravimetric analysis (TGA) of the crystalline hydrate Form-I of Amlodipine benzoate of the present invention;
  • Fig. 3 represents differential scanning calorimetry (DSC) of the crystalline hydrate Form-I of Amlodipine benzoate of the present invention
  • Fig. 4 represents an X-ray powder diffraction (XRPD) pattern of the crystalline Form-II of Amlodipine benzoate prepared as per Example 2;
  • Fig. 5 represents a thermal gravimetric analysis (TGA) of the crystalline Form -II of Amlodipine benzoate of the present invention;
  • Fig. 6 represents differential scanning calorimetry (DSC) of the crystalline Form-II of Amlodipine benzoate of the present invention
  • Fig. 7 represents an X-ray powder diffraction (XRPD) pattern of the crystalline Form-Ill of Amlodipine benzoate prepared as per Example 3;
  • Fig. 8 represents a thermal gravimetric analysis (TGA) of the crystalline Form-Ill of Amlodipine benzoate of the present invention
  • Fig. 9 represents differential scanning calorimetry (DSC) of the crystalline Form- Ill of Amlodipine benzoate of the present invention.
  • Fig. 10 represents an X-ray powder diffraction (XRPD) pattern of the crystalline monohydrate Form-IV of Amlodipine benzoate prepared as per Example 4;
  • Fig. 11 represents an X-ray powder diffraction (XRPD) pattern of the amorphous Amlodipine benzoate prepared as per Example 5;
  • the present invention provides crystalline hydrate of Amlodipine benzoate.
  • the crystalline hydrate of present invention contains from about 1.5% to about 12.7% w/w of water by Karl-Fischer titration.
  • the present invention provides a crystalline hydrate Form-I of Amlodipine benzoate.
  • the crystalline hydrate Form-I of Amlodipine benzoate contains about 6.3% w/w of water by Karl-Fischer titration.
  • the crystalline hydrate Form-I of Amlodipine benzoate according to the present invention is a di-hydrate of Amlodipine benzoate.
  • the crystalline dihydrate Form-I of Amlodipine benzoate is characterized by at least one of the following: a.
  • XRPD X-ray powder diffraction
  • XRPD X-ray powder diffraction
  • the crystalline dihydrate Form-I of Amlodipine benzoate can be further characterized by an X-ray diffraction (XRPD) pattern comprising peaks at about 9.7, 15.7, 19.2, 22.0, 24.9 and 25.6 ⁇ 0.2° 2Q.
  • XRPD X-ray diffraction
  • the present invention provides a process for preparing crystalline hydrate Form-I of Amlodipine benzoate, comprising: a. contacting phthaloyl amlodipine with monomethyl amine; optionally in methyl tert-butyl ether to obtain Amlodipine free base; b. contacting Amlodipine free base with benzoic acid in methyl tert-butyl ether; and c. isolating crystalline hydrate Form-I of Amlodipine benzoate.
  • Step (a) may be carried out at ambient temperatures to 70°C for the time sufficient to obtain Amlodipine free base.
  • the step (a) may be carried out at the temperature ranging from 20°C to 60°C for the time sufficient to obtain Amlodipine free base.
  • Step (a) may further involve extraction of Amlodipine free base using the solvent of step (a) or organic solvent selected from ethyl acetate or dichloromethane followed by optional separation of organic layer from the reaction mixture and washing thereof with brine or water.
  • Step (a) may further comprise isolation of Amlodipine free base from the reaction mixture as solid before contacting the same with benzoic acid.
  • Amlodipine free base is not isolated from the reaction mixture of Step (a) and the reaction mixture is directly contacted with benzoic acid.
  • Step (b) may be carried out at 0°C to 50°C for the time sufficient to obtain crystalline hydrate Form-I of Amlodipine benzoate.
  • the step (b) may be carried out at 10°C to ambient temperature for the time sufficient to obtain crystalline hydrate Form-I of Amlodipine benzoate.
  • Step (c), wherein the crystalline hydrate Form-I of Amlodipine benzoate may be isolated by methods such as precipitation, cooling, filtration, centrifugation or combinations thereof.
  • the crystalline hydrate Form-I may optionally be washed with methyl tert-butyl ether.
  • crystalline hydrate Form-I is dried by the methods such as vacuum drying, air drying, heat drying, freeze drying or supercritical drying. Any of the mentioned methods may also be used in combination to ensure removal of unbound solvent or water.
  • the crystalline hydrate Form-I of Amlodipine benzoate is dried by air, heat and/or vacuum drying methods.
  • a suitable drying temperature is, for example, from 35°C to 100°C, preferably from 40°C to70°C.
  • the drying time will be dependent upon, amongst other things, the amount of material to be dried, and the particular drying method used. Generally a drying time of 20 minutes to 25 hours, preferably 2 hours to 10 hours is sufficient.
  • the drying is performed by heating under vacuum and optionally under inert atmosphere, for example by passing a stream of warm inert gas such as nitrogen over or through material.
  • the present invention provides a crystalline anhydrous form of Amlodipine benzoate.
  • the crystalline anhydrous form of Amlodipine benzoate contains less than 1% w/w of water by Karl-Fischer titration.
  • the present invention provides a crystalline Form -II of Amlodipine benzoate.
  • the crystalline Form-II of Amlodipine benzoate contains about 0.21% w/w of water by Karl-Fischer titration.
  • the crystalline Form-II of Amlodipine benzoate is characterized by at least one of the following: a. an X-ray powder diffraction (XRPD) pattern comprising peaks at about 4.4, 6.0 and 12.1 ⁇ 0.2° 2Q and an X-ray powder diffraction (XRPD) pattern substantially the same as depicted in Fig. 4; b. by a weight loss of about less than 1% as measured by thermal gravimetric analysis (TGA) and a thermal gravimetric thermogram substantially the same as depicted in Fig. 5; or c. by DSC endotherm with onset temperature at 136.86°C and a DSC pattern substantially the same as depicted in Fig. 6.
  • XRPD X-ray powder diffraction
  • TGA thermal gravimetric analysis
  • a thermal gravimetric thermogram substantially the same as depicted in Fig. 5
  • the crystalline Form-II of Amlodipine benzoate can be further characterized by an X-ray diffraction (XRPD) pattern comprising peaks at about 8.5, 11.9, 19.9, 20.5, 20.9, 22.3, 23.0 and 23.8 ⁇ 0.2° 2Q.
  • XRPD X-ray diffraction
  • the present invention provides a process for preparing crystalline Form-II of Amlodipine benzoate, comprising: a. contacting phthaloyl amlodipine with monomethyl amine in methyl tert-butyl ether to obtain Amlodipine free base; b. removing water from the organic layer; c. contacting Amlodipine free base with benzoic acid in methyl tert-butyl ether; and d. isolating crystalline Form-II of Amlodipine benzoate.
  • Step (a) may be carried out at ambient temperatures to 70°C for the time sufficient to obtain Amlodipine free base.
  • the step (a) may be carried out at the temperature ranging from 20 to 60°C for the time sufficient to obtain Amlodipine free base.
  • Step (a) may further involve extraction of Amlodipine free base using the solvent of step (a) or organic solvent selected from ethyl acetate or dichloromethane followed by optional separation of organic layer from the reaction mixture and washing thereof with brine or water.
  • Step (b), wherein calculated amount of water may be removed by either of the methods known to the skilled practitioner, such as distillation, physical adsorption (molecular sieve, anhydrous sodium sulfate, anhydrous magnesium sulfate), chemical water removal or combination thereof.
  • the water is removed by distillation. More preferably, by carrying out azeotropic distillation using dean- stark apparatus.
  • Step (b) may further comprise isolation of Amlodipine free base from the reaction mixture as solid before contacting the same with benzoic acid.
  • Amlodipine free base is not isolated from the reaction mixture of Step (b) and the reaction mixture is directly contacted with benzoic acid.
  • Step (c) may be carried out at 0°C to 50°C for the time sufficient to obtain crystalline Form-II of Amlodipine benzoate.
  • the step c) may be carried out at 10°C to ambient temperature for the time sufficient to obtain crystalline Form-II of Amlodipine benzoate.
  • Step (d), wherein the crystalline Form-II of Amlodipine benzoate may be isolated by methods such as precipitation, cooling, filtration, centrifugation or combination thereof.
  • the crystalline Form-II may optionally be washed with methyl tert-butyl ether.
  • crystalline Form-II is dried by the methods such as vacuum drying, air drying, heat drying, freeze drying or supercritical drying. Any of the mentioned methods may also be used in combination to ensure removal of unbound solvent or water.
  • the crystalline Form-II of Amlodipine benzoate is dried by air, heat and/or vacuum drying methods.
  • a suitable drying temperature is, for example, from 35°C to 100°C, preferably from 40°C to70°C.
  • the drying time will be dependent upon, amongst other things, the amount of material to be dried, and the particular drying method used. Generally a drying time of 20 minutes to 25 hours, preferably 2 hours to 10 hours is sufficient.
  • the drying is performed by heating under vacuum and optionally under inert atmosphere, for example by passing a stream of warm inert gas such as nitrogen over or through material.
  • the present invention provides a crystalline Form-Ill of Amlodipine benzoate.
  • the crystalline Form-Ill of Amlodipine benzoate contains about 0.15% w/w of water.
  • the crystalline Form-Ill of Amlodipine benzoate is characterized by at least one of the following: a. an X-ray powder diffraction (XRPD) pattern comprising peaks at about 4.1 and 5.6 ⁇ 0.2° 2Q and an X-ray powder diffraction (XRPD) pattern substantially the same as depicted in Fig. 7; or b. by DSC endotherm with onset temperature at 125.96°C and a DSC pattern substantially the same as depicted in Fig. 9.
  • XRPD X-ray powder diffraction
  • XRPD X-ray powder diffraction
  • the crystalline Form-Ill of Amlodipine benzoate can be further characterized by an X-ray diffraction (XRPD) pattern comprising peaks at about 11.4, 12.3, 12.8, 15.5, 19.7, 23.8, 24.0 and 24.3 ⁇ 0.2° 2Q.
  • XRPD X-ray diffraction
  • the present invention provides a process for preparing crystalline Form-Ill of Amlodipine benzoate, comprising: a. contacting phthaloyl amlodipine with monomethyl amine in a solvent selected from the group comprising of hydrocarbon solvents, halogenated solvents or mixture thereof to obtain Amlodipine free base; b. contacting Amlodipine free base with benzoic acid in a solvent selected from the group comprising of hydrocarbon solvents, halogenated solvents or mixture thereof; and c. isolating crystalline Form-Ill of Amlodipine benzoate.
  • Steps (a) and (b), wherein the solvent may be selected from the group comprising toluene, xylene, dichloromethane or mixture thereof.
  • the solvent may be selected from toluene or dichloromethane. More preferably, the solvent is toluene.
  • Step (a) may be carried out at ambient temperatures to 120°C for the time sufficient to obtain Amlodipine free base.
  • the step (a) may be carried out at the temperature ranging from 20°C to 60°C for the time sufficient to obtain Amlodipine free base.
  • Step (a) may further involve extraction of Amlodipine free base using the solvent of step (a) or organic solvent selected from ethyl acetate or dichloromethane followed by optional separation of organic layer from the reaction mixture and washing thereof with brine or water.
  • Step (a) may further comprise isolation of Amlodipine free base from the reaction mixture as solid before contacting the same with benzoic acid.
  • Amlodipine free base is not isolated from the reaction mixture of Step (a) and the reaction mixture is directly contacted with benzoic acid.
  • Step (b) may be carried out at 0°C to 50°C for the time sufficient to obtain crystalline Form-Ill of Amlodipine benzoate.
  • the step (b) may be carried out at 10°C to ambient temperature for the time sufficient to obtain crystalline Form-Ill of Amlodipine benzoate.
  • Step (c), wherein the crystalline Form-Ill of Amlodipine benzoate may be isolated by methods such as precipitation, cooling, filtration, centrifugation or combination thereof.
  • the crystalline Form-Ill may optionally be washed with the solvent selected from toluene, xylene, dichloromethane or mixture thereof.
  • the crystalline Form-Ill is dried by the methods such as vacuum drying, air drying, heat drying, freeze drying or supercritical drying. Any of the mentioned methods may also be used in combination to ensure removal of unbound solvent or water.
  • the crystalline Form-Ill of Amlodipine benzoate is dried by air, heat and/or vacuum drying methods.
  • a suitable drying temperature is, for example, from 35°C to 100°C, preferably from 40°C to70°C.
  • the drying time will be dependent upon, amongst other things, the amount of material to be dried, and the particular drying method used. Generally a drying time of 20 minutes to 25 hours, preferably 2 hours to 10 hours is sufficient.
  • the drying is performed by heating under vacuum and optionally under inert atmosphere, for example by passing a stream of warm inert gas such as nitrogen over or through material.
  • the present invention provides a crystalline monohydrate Form-IV of Amlodipine benzoate.
  • the crystalline Form-IV of Amlodipine benzoate contains about 0.15% w/w of water.
  • the crystalline monohydrate Form-IV of Amlodipine benzoate is characterized by X-ray powder diffraction (XRPD) pattern comprising peaks at about 4.1 and 5.6 ⁇ 0.2° 2Q and an X-ray powder diffraction (XRPD) pattern substantially the same as depicted in Fig. 10;
  • the crystalline monohydrate Form-IV of Amlodipine benzoate can be further characterized by an X-ray diffraction (XRPD) pattern comprising peaks at about 4.1, 5.6, 11.4, 12.3, 12.8, 15.5, 19.7, 23.8, 24.0 and 24.3 ⁇ 0.2° 2Q.
  • XRPD X-ray diffraction
  • the present invention provides a process for preparing crystalline Form-IV of Amlodipine benzoate, comprising: a. contacting phthaloyl amlodipine with monomethyl amine to obtain Amlodipine free base; b. contacting Amlodipine free base with benzoic acid in a ethyl acetate; and c. isolating crystalline monohydrate Form-IV of Amlodipine benzoate.
  • the present invention provides a process for preparing Amlodipine benzoate, comprising: a. contacting phthaloyl amlodipine with monomethyl amine optionally in a solvent to obtain Amlodipine free base; b. contacting Amlodipine free base with benzoic acid in a solvent; and c. isolating Amlodipine benzoate.
  • the solvent may be selected from ethanol, methyl tert-butyl ether, toluene or mixture thereof. More preferably, the solvent may be selected from methyl tert-butyl ether, ethyl acetate or toluene.
  • Step (a) may be carried out at ambient temperatures to 70°C for the time sufficient to obtain Amlodipine free base.
  • the step (a) may be carried out at the temperature ranging from 20°C to 60°C for the time sufficient to obtain Amlodipine free base.
  • Step (a) may further involve extraction of Amlodipine free base using the organic solvent of step (a) or organic solvent selected from ethyl acetate or dichloromethane followed by optional separation of organic layer from the reaction mixture and washing thereof with brine or water.
  • Step (a) may further comprise removal of calculated amount of water from the organic layer by either of the methods known to the skilled practitioner, such as distillation, physical adsorption (molecular sieve, anhydrous sodium sulfate, anhydrous magnesium sulfate), chemical water removal or combination thereof.
  • the water may be removed by distillation. More preferably, by carrying out azeotropic distillation using dean-stark apparatus.
  • Step (a) may further comprise isolation of Amlodipine free base from the reaction mixture as solid before contacting the same with benzoic acid.
  • Amlodipine free base is not isolated from the reaction mixture of Step (a) and the reaction mixture is directly contacted with benzoic acid.
  • Step (b) may be carried out at 0°C to 50°C for the time sufficient to obtain Amlodipine benzoate.
  • the step (b) may be carried out at 10°C to ambient temperature for the time sufficient to obtain Amlodipine benzoate.
  • Step (c), wherein Amlodipine benzoate may be isolated by methods such as precipitation, cooling, filtration, centrifugation or combination thereof.
  • the isolated Amlodipine benzoate may optionally be washed with a solvent selected from the group comprising of water, methanol, ethanol, diethyl-ether, methyl tert-butyl ether, ethyl acetate, 1,4-dioxane, dichloromethane, heptane, xylene, toluene or mixture thereof.
  • a solvent selected from the group comprising of water, methanol, ethanol, diethyl-ether, methyl tert-butyl ether, ethyl acetate, 1,4-dioxane, dichloromethane, heptane, xylene, toluene or mixture thereof.
  • a solvent selected from the group comprising of water, methanol, ethanol, diethyl-ether,
  • Amlodipine benzoate is dried by air, heat and/or vacuum drying methods.
  • a suitable drying temperature is, for example, from 35°C to 100°C, preferably from 40°C to70°C.
  • the drying time will be dependent upon, amongst other things, the amount of material to be dried, and the particular drying method used. Generally a drying time of 20 minutes to 25 hours, preferably 2 hours to 10 hours is sufficient.
  • the drying is performed by heating under vacuum and optionally under inert atmosphere, for example by passing a stream of warm inert gas such as nitrogen over or through material.
  • the present invention provides a crystalline form of Amlodipine benzoate having a purity by HPLC of >99%.
  • a purity by HPLC of >99.5% more particularly, a purity by HPLC of >99.8%, most particularly, a purity by HPLC of >99.9%.
  • compositions comprising Amlodipine Benzoate in an amorphous form or crystalline Form 1, Form -II, Form -III, Form- IV or a acceptable hydrate or solvate thereof, as an active pharmaceutical ingredient, in combination with one or more pharmaceutically acceptable carriers or excipients.
  • excipients to a large extent, depends on factors, such as the particular mode of administration, the effect of the excipient on the solubility and stability of the active ingredient, and the nature of the dosage form.
  • the pharmaceutical composition described herein is preferably an Amlodipine Oral Liquid Formulation.
  • the oral liquids pharmaceutical composition may include, but are not limited to, solutions (both aqueous and nonaqueous), suspensions, emulsions, syrups, slurries, juices, elixirs, dispersions, and the like. It is envisioned that solution/suspensions are also included where certain components described herein are in a solution while other components are in a suspension. In some embodiments, the oral liquid formulation is a suspension.
  • XRPD X-ray diffraction data is obtained using a Bruker AXS D8 advance (or) equivalent X-ray Diffractometer, CuKa radiation, wavelength 1.54 A.
  • TGA TGA measurement is performed using a TGA55; TRIOS software V4.3.1.39215, temperature range 30°C-300°C and 10°C/min.
  • DSC DSC measurement is performed using DSC25; TRIOS software V4.3.1.39215, temperature range 25°C-300°C and 5°C/min.
  • KF KF results is obtained using Metrohm; 870KF Titrino plus.
  • Example-1 Process of Crystalline hydrate Form-I of Amlodipine benzoate
  • Phthaloyl amlodipine (25.0 g, 1 equivalent) was treated with aqueous monomethyl amine solution (Aqueous 40%, 75 ml, 3.0 volumes) at 30°C-50°C in methyl tert-butyl ether (250 ml, 10.0 volume). After completion of reaction, organic layer was separated and aqueous layer back extracted with methyl tert-butyl ether (50 ml X 2 times). Washed the combined methyl tert-butyl ether layer with water (50 ml X 2 times).
  • Example-la Process of crystalline dihydrate Form I of Amlodipine benzoate
  • Phthaloyl amlodipine (301.5 gm, 1 equivalent) was treated with aqueous monomethyl amine solution (Aqueous 40%, 1200 ml, 4.0 volumes) at 30°C-37°C and maintained for 12 hours.
  • aqueous monomethyl amine solution (Aqueous 40%, 150 ml, 0.5 volumes) at 30°C-37°C, stirred for 12 and then stirred for 8 hours at 40°C-46 0 C.
  • water 600 ml, 2 volume
  • the isolated solid was washed with water (1200 ml, 4 volume).
  • the isolated wet solid was partitioned between ethyl acetate (2400 ml, 8 volume) and water (300 ml,
  • Example-2 Process of Crystalline Form-II of Amlodipine benzoate Phthaloyl amlodipine (50g, 1.0 equivalent) was treated with aqueous monomethyl amine solution (Aqueous 40%, 200 ml, 4.0 volume) at 30°C -50°C in methyl tert- butyl ether (500ml, 10.0 volume). After completion of reaction, organic layer was separated and aqueous layer back extracted with methyl tert-butyl ether (100 ml X 2 times). Washed the combined methyl tert-butyl ether layer was washed water (100 ml X 2 times).
  • Example-3 Process of crystalline Form-Ill of Amlodipine benzoate
  • Phthaloyl amlodipine (20g, 1 equivalent) was treated with aqueous monomethyl amine solution (Aqueous 40%, 80 ml, 4.0 volume) at 30°C -50 °C in toluene (100 ml, 5.0 volume). After completion of reaction, organic layer was separated and aqueous layer back extracted with toluene (20 ml X 2 times). Washed the combined toluene layer with water (40 ml X 3 times). Distilled out approximately 1.0 volume of toluene (20 ml) under vacuum below 40°C. Cooled the reaction mass to 10°C -30°C and added toluene (180ml, 9.0 volume) to the reaction mass.
  • Example-4 Process of crystalline monohydrate Form IV of Amlodipine benzoate
  • Phthaloyl amlodipine (151.0 gm, 1 equivalent) was treated with aqueous monomethyl amine solution (Aqueous 40%, 600 ml, 4.0 volumes) at 25°C -35 0 C and maintained for 23 hours. After completion of reaction, added water (300 ml, 2 volume) into the reaction mass and filtered the solid after maintaining the reaction mass at 0°C -10°C for 2 hours. The isolated solid was washed with water (600 ml, 4 volume).
  • the isolated wet solid (20gm equivalent) was dissolved in ethyl acetate (200 ml, 10 volume) and cooled to 0°C -10 °C followed by addition of benzoic acid (4.1 gm, 0.90 equivalent) dissolved in the ethyl acetate (40 ml, 2 volume).
  • the wet solid was isolated after filtration followed by ethyl acetate washing (40 ml, 2 volume).
  • the Amlodipine benzoate monohydrate was obtained after drying the wet solid at 30°C - 42 °C for 8 hours.
  • Phthaloyl amlodipine (lOOg, 1.0 equivalent) was treated with aqueous monomethyl amine solution (Aqueous 40%, 400 ml, 4.0 volume) at 30°C -50 °C in methyl tert- butyl ether (1000ml, 10.0 volume) for 8-10 hours. After completion of reaction, organic layer was separated and aqueous layer back extracted with methyl tert-butyl ether (200 ml X 2 times). Washed the combined methyl tert-butyl ether layer was washed water (200 ml X 4 times). Added methyl tert-butyl ether (200 ml, 2.0 volume) in to the organic layer and filtered through Cellite bed.
  • aqueous monomethyl amine solution Aqueous 40%, 400 ml, 4.0 volume
  • methyl tert-butyl ether 1000ml, 10.0 volume
  • organic layer was separated and aqueous layer back extracted with methyl tert-butyl

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to the polymorphic forms of Amlodipine benzoate and pharmaceutical compositions thereof. Particularly, the present invention relates to crystalline hydrate and crystalline anhydrous forms of Amlodipine benzoate. The present invention also relates to the processes for the preparation of polymorphic forms of the present invention. Further, the present invention relates to a process for the preparation of Amlodipine benzoate.

Description

DESPCRIPTION
TITLE:
POLYMORPHIC FORMS OF AMLODIPINE BENZOATE AND PROCESS FOR THE PREPARATION THEREOF
FIELD OF INVENTION
The present invention relates to the polymorphic forms of Amlodipine benzoate and pharmaceutical compositions thereof. The present invention also relates to the processes for the preparation of Amlodipine benzoate. The present invention further relates to the manufacturing processes for the preparation of crystalline Amlodipine benzoate.
BACKGROUND OF THE INVENTION
Amlodipine benzoate, chemically known as 3-Ethyl-5-methyl (±)-2-[(2- aminoethoxy)methyl]-4-(2-chlorophenyl)-l,4-dihydro-6-methyl-3,5- pyridinedicarboxylate benzenecarboxylate is benzoate salt of Amlodipine and is represented by the formula I.
Figure imgf000002_0001
Amlodipine benzoate is the active ingredient of the drug Katerzia® and intended for oral suspension. Amlodipine benzoate is a calcium channel blocker and is intended for the treatment of hypertension by reducing the blood pressure and thus reducing the risk of various cardiovascular events. Prior to Katrezia®, W02005/089353 generically disclosed (S)- Amlodipine benzoate as the first intermediate salt during the preparation of (S)-Amlodipine maleate. Though, the PCT doesn’t disclose specific preparation or isolation of (S)-Amlodipine benzoate. CN110372575 discloses eutectic crystal of dihydropyridine calcium antagonist. The disclosed eutectic crystal has molecular formula: (C20H25CIN2O5) (CeHsCOOH) (Y)n, wherein Y is any one of water molecule, ethanol molecule or isopropanol molecule, 0<n<3, C20H25CIN2O5 is levamlodipine, C6H5COOH is benzoic acid.
WO20 18/067959 relates to the oral liquid formulation of Amlodipine benzoate, wherein the process for the preparation of oral liquid formulation comprises formation of Amlodipine benzoate in situ by reaction of more aqueous soluble Amlodipine salt (Amlodipine besylate or other Amlodipine salts) than Amlodipine benzoate, with a molar excess of sodium benzoate in the presence of at least one additional excipient. A particular polymorphic form of a compound may have certain physical properties that differ from those of any other crystalline or amorphous forms and such properties may influence markedly the chemical and pharmaceutical processing of compound, particularly when the compound is prepared or used on a commercial scale. For example, each crystal form of a compound may show differences in physical properties such as crystalline size and shape, melting point, density, hygroscopicity, solubility, suspending properties and stability. In general, the more stable crystalline form is more suitable for formulation and processing on a commercial scale. Amlodipine and its various pharmaceutically acceptable salts have been studied since decades. US4572909 disclosed Amlodipine and pharmaceutically acceptable salts such as, hydrochloride, hydrobromide, sulphate, phosphate or acid phosphate, acetate, maleate, fumarate, lactate, tartrate, citrate and gluconate salts. US4879303 & US6846931 disclosed Amlodipine besylate and Amlodipine pyroglutamate, respectively. Further, there are several prior-arts disclosing preparation of these salts, wherein the process comprises conversion of protected Amlodipine to Amlodipine free base followed by its conversion to desired salt. Particularly, US20020143046, W02005023769, CN102659673, CN105732482, CN103006648 and CN107445889 discloses conversion of Phthaloyl Amlodipine to Amlodipine free base followed by its conversion to desired salt, preferably in situ (without free base isolation). Wherein Phthaloyl amlodipine is preferably treated with aqueous solutions of primary amines in water immiscible solvents followed by treatment of the organic phase with suitable organic acids to give amlodipine in the form of a pharmaceutically acceptable salt. Generic representation of conversion of Phthaloyl Amlodipine to Amlodipine Salt can be depicted as Scheme-1:
Figure imgf000004_0001
Though, none of these prior art explicitly discloses preparation of Amlodipine benzoate, W02019/200143 discloses a process for conversion of Amlodipine salt (preferably besylate) having more aqueous solubility to Amlodipine benzoate in the presence of sodium benzoate by ultrasonic agitation. The process disclosed therein has one or more issues while scaling up, particularly ultrasonic agitation step. Further, the process comprise conversion of the first Amlodipine salt to final Amlodipine benzoate. Thus, the overall Amlodipine benzoate manufacturing process comprises an additional step of isolating the first Amlodipine salt. The inventors of the present invention have developed novel Amlodipine benzoate crystalline forms, possessing desirable processing properties. Also, the inventors of the present invention have addressed the need of developing an industrial viable process for the preparation of Amlodipine benzoate which can overcome the drawbacks associated with the known processes and result in the desired polymorph of Amlodipine benzoate with substantial purity and yield.
OBJECTIVE OF THE INVENTION
The primary objective of the present invention is to provide novel polymorphic forms of Amlodipine benzoate and pharmaceutical compositions thereof. Another objective of the present invention is to provide an industrial viable process for the synthesis of Amlodipine benzoate.
Another objective of the present invention is to provide a process for the preparation of novel polymorphic forms of Amlodipine benzoate.
SUMMARY OF THU INVENTION In one general aspect, the present invention provides a crystalline hydrate of Amlodipine benzoate.
In another general aspect, the present invention provides a crystalline dihydrate Form-I of Amlodipine benzoate characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at about 4.9, 10.7 and 13.7±0.2° 2Q.
In another general aspect, the present invention provides a process for preparing crystalline hydrate Form-I of Amlodipine benzoate, comprising: a. contacting phthaloyl amlodipine with monomethyl amine in methyl tert-butyl ether to obtain Amlodipine free base; b. contacting Amlodipine free base with benzoic acid in methyl tert-butyl ether; and c. isolating crystalline hydrate Form-I of Amlodipine benzoate. In another general aspect, the present invention provides a process for preparing crystalline hydrate Form-I of Amlodipine benzoate, comprising: a. contacting phthaloyl amlodipine with monomethyl amine to obtain amlodipine free base; b. contacting Amlodipine free base with benzoic acid in ethyl acetate and water; and c. isolating crystalline hydrate Form-I of Amlodipine benzoate. In another general aspect, the present invention provides crystalline anhydrous form of Amlodipine benzoate.
In another general aspect, the present invention provides a crystalline Form-II of Amlodipine benzoate characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at about 4.4, 6.0 and 12.1±0.2° 2Q.
In another general aspect, the present invention provides a process for preparing crystalline Form-II of Amlodipine benzoate, comprising: a. contacting phthaloyl amlodipine with monomethyl amine in methyl tert-butyl ether to obtain Amlodipine free base; b. removing water from the organic layer; c. contacting Amlodipine free base with benzoic acid in methyl tert-butyl ether; and d. isolating crystalline Form-II of Amlodipine benzoate.
In another general aspect, the present invention provides a crystalline Form-Ill of Amlodipine benzoate characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at about 4.1 and 5.6±0.2° 2Q.
In another general aspect, the present invention provides a process for preparing crystalline Form-Ill of Amlodipine benzoate, comprising: a. contacting phthaloyl amlodipine with monomethyl amine in a solvent, selected from the group comprising of hydrocarbon solvents, halogenated solvents or mixture thereof to obtain Amlodipine free base; b. contacting Amlodipine free base with benzoic acid in a solvent, selected from the group comprising of hydrocarbon solvents, halogenated solvents or mixture thereof; and c. isolating crystalline Form-Ill of Amlodipine benzoate.
In another general aspect, the present invention provides a crystalline monohydrate Form-IV of Amlodipine benzoate characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at about 6.71 and 7.93±0.2° 2Q. In another general aspect, the present invention provides a process for preparing crystalline monohydrate Form-IV of Amlodipine benzoate, comprising: a. contacting phthaloyl amlodipine with monomethyl amine to obtain amlodipine free base; b. contacting Amlodipine free base with benzoic acid in a Ethyl acetate; and c. isolating crystalline monohydrate Form-IV of Amlodipine benzoate.
In another general aspect, the present invention provides a process for preparing Amlodipine benzoate, comprising: a. contacting phthaloyl amlodipine with monomethyl amine in a solvent to obtain Amlodipine free base; b. contacting Amlodipine free base with benzoic acid in a solvent; and c. isolating Amlodipine benzoate.
In another general aspect, the present invention provides an amorphous Amlodipine benzoate.
In another general aspect, the present invention provides a pharmaceutical composition containing a hydrate, crystalline form or amorphous form of Amlodipine benzoate.
DEFINITIONS As used herein, the term “ambient temperature” refers to a temperature ranging from about 15°C to 35°C, preferably the ambient temperature refers to a temperature from about 20°C to 30°C, more preferably to a temperature of 25°C.
The terms “comprising” and “comprises” mean the elements recited, or their equivalents in structure or function, plus any other element or elements which are not recited. The term “optionally” or “optional” is taken to mean that the event or circumstance describes in the specification may or may not occur, and that the description includes instances where the event occurs and instances where it does not.
As used herein, the term “hydrate” refers to the crystalline solid adducts containing either stoichiometric or nonstoichiometric amounts of water incorporated within the crystal structure. Hydrates can be defined based on the moles of water incorporated within the crystal structure one mole of Amlodipine benzoate. “Monohydrate” stands for one mole of water with respect to one mole of Amlodipine benzoate; “dihydrate” stands for two moles of water with respect to one mole of Amlodipine benzoate; and similarly “hemihydrate” and “sesquihydrate” stands for half and 1.5 moles of water with respect to one mole of Amlodipine benzoate. The same can be indicated as percentage (%) weight of water with respect to weight of Amlodipine benzoate. The percentage (%) weight of water can be obtained by various analytical tools; preferably, Karl-Fischer titration and Thermal Gravimetric Analysis.
As used herein, the term “anhydrous” refers to the crystalline or amorphous solid adducts containing undetectable bound water, incorporated within the crystal structure.
As used herein, the term “remove water” or “removing water” stands for removing or separating trace amount of water from a mixture of organic solution with water by the means of distillation, physical adsorption or chemical methods.
As used herein, the term “azeotropically” or “azeotropic distillation” stands for the process to break azeotrope and to separate two close-boiling components, facilitated by dean-stark apparatus.
As used herein, the term “contacting” includes mixing, adding, slurrying, stirring or a combination thereof.
As used herein, the term “about” are to be construed as modifying a term or value such that it is not an absolute. Such terms will be defined by the circumstances. This includes, at the very least, the degree of expected experimental error, technique error and instrument error for a given technique used to measure a value.
The term “substantially the same” with reference to analytical characterization such as X-ray powder diffraction (XRPD) peak positions or TGA thermogram endothermic / exothermic peak positions means that typical peak position and intensity variability are taken into account. For example, one skilled in the art will appreciate that the peak position (2 theta) will show some inter-apparatus variability, typically as much as 0.2°. Further, one skilled in the art will appreciate that relative peak intensities will show inter-apparatus variability as well as variability due to degree of crystallinity, preferred orientation, prepared sample surface and other factors known to those skilled in the art and should be taken as quantitative measure only.
ABBREVIATIONS
XRPD X-Ray Powder Diffraction
TGA Thermal Gravimetric Analysis
DSC Differential Scanning Calorimetry
KF Karl Fischer Titration
HPLC High Performance Liquid Chromatography BRIEF DESCRIPTION OF FIGURES
Fig. 1 represents an X-ray powder diffraction (XRPD) pattern of the crystalline hydrate Form-I of Amlodipine benzoate prepared as per Example 1; Fig. 2 represents a thermal gravimetric analysis (TGA) of the crystalline hydrate Form-I of Amlodipine benzoate of the present invention;
Fig. 3 represents differential scanning calorimetry (DSC) of the crystalline hydrate Form-I of Amlodipine benzoate of the present invention;
Fig. 4 represents an X-ray powder diffraction (XRPD) pattern of the crystalline Form-II of Amlodipine benzoate prepared as per Example 2; Fig. 5 represents a thermal gravimetric analysis (TGA) of the crystalline Form -II of Amlodipine benzoate of the present invention;
Fig. 6 represents differential scanning calorimetry (DSC) of the crystalline Form-II of Amlodipine benzoate of the present invention;
Fig. 7 represents an X-ray powder diffraction (XRPD) pattern of the crystalline Form-Ill of Amlodipine benzoate prepared as per Example 3;
Fig. 8 represents a thermal gravimetric analysis (TGA) of the crystalline Form-Ill of Amlodipine benzoate of the present invention;
Fig. 9 represents differential scanning calorimetry (DSC) of the crystalline Form- Ill of Amlodipine benzoate of the present invention.
Fig. 10 represents an X-ray powder diffraction (XRPD) pattern of the crystalline monohydrate Form-IV of Amlodipine benzoate prepared as per Example 4;
Fig. 11 represents an X-ray powder diffraction (XRPD) pattern of the amorphous Amlodipine benzoate prepared as per Example 5;
PET ATT, ED DESCRIPTION OF THE INVENTION
In one general aspect, the present invention provides crystalline hydrate of Amlodipine benzoate. The crystalline hydrate of present invention contains from about 1.5% to about 12.7% w/w of water by Karl-Fischer titration.
In one another aspect, the present invention provides a crystalline hydrate Form-I of Amlodipine benzoate. The crystalline hydrate Form-I of Amlodipine benzoate contains about 6.3% w/w of water by Karl-Fischer titration. The crystalline hydrate Form-I of Amlodipine benzoate according to the present invention is a di-hydrate of Amlodipine benzoate. The crystalline dihydrate Form-I of Amlodipine benzoate is characterized by at least one of the following: a. an X-ray powder diffraction (XRPD) pattern comprising peaks at about 4.9, 10.7 and 13.7±0.2° 2Q and an X-ray powder diffraction (XRPD) pattern substantially the same as depicted in Fig. 1; b. by a weight loss of about 5.6% as measured by thermal gravimetric analysis (TGA) and a thermal gravimetric thermogram substantially the same as depicted in Fig. 2; or c. by DSC endotherm with onset temperature at 87.24°C and a DSC pattern substantially the same as depicted in Fig. 3.
The crystalline dihydrate Form-I of Amlodipine benzoate can be further characterized by an X-ray diffraction (XRPD) pattern comprising peaks at about 9.7, 15.7, 19.2, 22.0, 24.9 and 25.6±0.2° 2Q.
In one another aspect, the present invention provides a process for preparing crystalline hydrate Form-I of Amlodipine benzoate, comprising: a. contacting phthaloyl amlodipine with monomethyl amine; optionally in methyl tert-butyl ether to obtain Amlodipine free base; b. contacting Amlodipine free base with benzoic acid in methyl tert-butyl ether; and c. isolating crystalline hydrate Form-I of Amlodipine benzoate.
Step (a) may be carried out at ambient temperatures to 70°C for the time sufficient to obtain Amlodipine free base. Preferably the step (a) may be carried out at the temperature ranging from 20°C to 60°C for the time sufficient to obtain Amlodipine free base. Step (a) may further involve extraction of Amlodipine free base using the solvent of step (a) or organic solvent selected from ethyl acetate or dichloromethane followed by optional separation of organic layer from the reaction mixture and washing thereof with brine or water. Step (a) may further comprise isolation of Amlodipine free base from the reaction mixture as solid before contacting the same with benzoic acid. Alternatively, Amlodipine free base is not isolated from the reaction mixture of Step (a) and the reaction mixture is directly contacted with benzoic acid.
Step (b) may be carried out at 0°C to 50°C for the time sufficient to obtain crystalline hydrate Form-I of Amlodipine benzoate. Preferably the step (b) may be carried out at 10°C to ambient temperature for the time sufficient to obtain crystalline hydrate Form-I of Amlodipine benzoate.
Step (c), wherein the crystalline hydrate Form-I of Amlodipine benzoate may be isolated by methods such as precipitation, cooling, filtration, centrifugation or combinations thereof. The crystalline hydrate Form-I may optionally be washed with methyl tert-butyl ether.
Thus obtained crystalline hydrate Form-I is dried by the methods such as vacuum drying, air drying, heat drying, freeze drying or supercritical drying. Any of the mentioned methods may also be used in combination to ensure removal of unbound solvent or water. Preferably the crystalline hydrate Form-I of Amlodipine benzoate is dried by air, heat and/or vacuum drying methods. A suitable drying temperature is, for example, from 35°C to 100°C, preferably from 40°C to70°C. As may be recognized, the drying time will be dependent upon, amongst other things, the amount of material to be dried, and the particular drying method used. Generally a drying time of 20 minutes to 25 hours, preferably 2 hours to 10 hours is sufficient. Conveniently the drying is performed by heating under vacuum and optionally under inert atmosphere, for example by passing a stream of warm inert gas such as nitrogen over or through material.
In one another aspect, the present invention provides a crystalline anhydrous form of Amlodipine benzoate. The crystalline anhydrous form of Amlodipine benzoate contains less than 1% w/w of water by Karl-Fischer titration. In one another aspect, the present invention provides a crystalline Form -II of Amlodipine benzoate. The crystalline Form-II of Amlodipine benzoate contains about 0.21% w/w of water by Karl-Fischer titration.
The crystalline Form-II of Amlodipine benzoate is characterized by at least one of the following: a. an X-ray powder diffraction (XRPD) pattern comprising peaks at about 4.4, 6.0 and 12.1±0.2° 2Q and an X-ray powder diffraction (XRPD) pattern substantially the same as depicted in Fig. 4; b. by a weight loss of about less than 1% as measured by thermal gravimetric analysis (TGA) and a thermal gravimetric thermogram substantially the same as depicted in Fig. 5; or c. by DSC endotherm with onset temperature at 136.86°C and a DSC pattern substantially the same as depicted in Fig. 6.
The crystalline Form-II of Amlodipine benzoate can be further characterized by an X-ray diffraction (XRPD) pattern comprising peaks at about 8.5, 11.9, 19.9, 20.5, 20.9, 22.3, 23.0 and 23.8±0.2° 2Q.
In one another aspect, the present invention provides a process for preparing crystalline Form-II of Amlodipine benzoate, comprising: a. contacting phthaloyl amlodipine with monomethyl amine in methyl tert-butyl ether to obtain Amlodipine free base; b. removing water from the organic layer; c. contacting Amlodipine free base with benzoic acid in methyl tert-butyl ether; and d. isolating crystalline Form-II of Amlodipine benzoate.
Step (a) may be carried out at ambient temperatures to 70°C for the time sufficient to obtain Amlodipine free base. Preferably the step (a) may be carried out at the temperature ranging from 20 to 60°C for the time sufficient to obtain Amlodipine free base. Step (a) may further involve extraction of Amlodipine free base using the solvent of step (a) or organic solvent selected from ethyl acetate or dichloromethane followed by optional separation of organic layer from the reaction mixture and washing thereof with brine or water.
Step (b), wherein calculated amount of water may be removed by either of the methods known to the skilled practitioner, such as distillation, physical adsorption (molecular sieve, anhydrous sodium sulfate, anhydrous magnesium sulfate), chemical water removal or combination thereof. Preferably, the water is removed by distillation. More preferably, by carrying out azeotropic distillation using dean- stark apparatus.
Step (b) may further comprise isolation of Amlodipine free base from the reaction mixture as solid before contacting the same with benzoic acid. Alternatively, Amlodipine free base is not isolated from the reaction mixture of Step (b) and the reaction mixture is directly contacted with benzoic acid.
Step (c) may be carried out at 0°C to 50°C for the time sufficient to obtain crystalline Form-II of Amlodipine benzoate. Preferably the step c) may be carried out at 10°C to ambient temperature for the time sufficient to obtain crystalline Form-II of Amlodipine benzoate.
Step (d), wherein the crystalline Form-II of Amlodipine benzoate may be isolated by methods such as precipitation, cooling, filtration, centrifugation or combination thereof. The crystalline Form-II may optionally be washed with methyl tert-butyl ether.
Thus obtained crystalline Form-II is dried by the methods such as vacuum drying, air drying, heat drying, freeze drying or supercritical drying. Any of the mentioned methods may also be used in combination to ensure removal of unbound solvent or water. Preferably the crystalline Form-II of Amlodipine benzoate is dried by air, heat and/or vacuum drying methods. A suitable drying temperature is, for example, from 35°C to 100°C, preferably from 40°C to70°C. As may be recognized, the drying time will be dependent upon, amongst other things, the amount of material to be dried, and the particular drying method used. Generally a drying time of 20 minutes to 25 hours, preferably 2 hours to 10 hours is sufficient. Conveniently the drying is performed by heating under vacuum and optionally under inert atmosphere, for example by passing a stream of warm inert gas such as nitrogen over or through material.
In one another aspect, the present invention provides a crystalline Form-Ill of Amlodipine benzoate. The crystalline Form-Ill of Amlodipine benzoate contains about 0.15% w/w of water. The crystalline Form-Ill of Amlodipine benzoate is characterized by at least one of the following: a. an X-ray powder diffraction (XRPD) pattern comprising peaks at about 4.1 and 5.6±0.2° 2Q and an X-ray powder diffraction (XRPD) pattern substantially the same as depicted in Fig. 7; or b. by DSC endotherm with onset temperature at 125.96°C and a DSC pattern substantially the same as depicted in Fig. 9.
The crystalline Form-Ill of Amlodipine benzoate can be further characterized by an X-ray diffraction (XRPD) pattern comprising peaks at about 11.4, 12.3, 12.8, 15.5, 19.7, 23.8, 24.0 and 24.3±0.2° 2Q.
In one another aspect, the present invention provides a process for preparing crystalline Form-Ill of Amlodipine benzoate, comprising: a. contacting phthaloyl amlodipine with monomethyl amine in a solvent selected from the group comprising of hydrocarbon solvents, halogenated solvents or mixture thereof to obtain Amlodipine free base; b. contacting Amlodipine free base with benzoic acid in a solvent selected from the group comprising of hydrocarbon solvents, halogenated solvents or mixture thereof; and c. isolating crystalline Form-Ill of Amlodipine benzoate.
Steps (a) and (b), wherein the solvent may be selected from the group comprising toluene, xylene, dichloromethane or mixture thereof. Preferably, the solvent may be selected from toluene or dichloromethane. More preferably, the solvent is toluene. Step (a) may be carried out at ambient temperatures to 120°C for the time sufficient to obtain Amlodipine free base. Preferably the step (a) may be carried out at the temperature ranging from 20°C to 60°C for the time sufficient to obtain Amlodipine free base. Step (a) may further involve extraction of Amlodipine free base using the solvent of step (a) or organic solvent selected from ethyl acetate or dichloromethane followed by optional separation of organic layer from the reaction mixture and washing thereof with brine or water.
Step (a) may further comprise isolation of Amlodipine free base from the reaction mixture as solid before contacting the same with benzoic acid. Alternatively, Amlodipine free base is not isolated from the reaction mixture of Step (a) and the reaction mixture is directly contacted with benzoic acid.
Step (b) may be carried out at 0°C to 50°C for the time sufficient to obtain crystalline Form-Ill of Amlodipine benzoate. Preferably the step (b) may be carried out at 10°C to ambient temperature for the time sufficient to obtain crystalline Form-Ill of Amlodipine benzoate.
Step (c), wherein the crystalline Form-Ill of Amlodipine benzoate may be isolated by methods such as precipitation, cooling, filtration, centrifugation or combination thereof. The crystalline Form-Ill may optionally be washed with the solvent selected from toluene, xylene, dichloromethane or mixture thereof.
Thus obtained crystalline Form-Ill is dried by the methods such as vacuum drying, air drying, heat drying, freeze drying or supercritical drying. Any of the mentioned methods may also be used in combination to ensure removal of unbound solvent or water. Preferably, the crystalline Form-Ill of Amlodipine benzoate is dried by air, heat and/or vacuum drying methods. A suitable drying temperature is, for example, from 35°C to 100°C, preferably from 40°C to70°C. As may be recognized, the drying time will be dependent upon, amongst other things, the amount of material to be dried, and the particular drying method used. Generally a drying time of 20 minutes to 25 hours, preferably 2 hours to 10 hours is sufficient. Conveniently the drying is performed by heating under vacuum and optionally under inert atmosphere, for example by passing a stream of warm inert gas such as nitrogen over or through material.
In one another aspect, the present invention provides a crystalline monohydrate Form-IV of Amlodipine benzoate. The crystalline Form-IV of Amlodipine benzoate contains about 0.15% w/w of water.
The crystalline monohydrate Form-IV of Amlodipine benzoate is characterized by X-ray powder diffraction (XRPD) pattern comprising peaks at about 4.1 and 5.6±0.2° 2Q and an X-ray powder diffraction (XRPD) pattern substantially the same as depicted in Fig. 10;
The crystalline monohydrate Form-IV of Amlodipine benzoate can be further characterized by an X-ray diffraction (XRPD) pattern comprising peaks at about 4.1, 5.6, 11.4, 12.3, 12.8, 15.5, 19.7, 23.8, 24.0 and 24.3±0.2° 2Q.
In one another aspect, the present invention provides a process for preparing crystalline Form-IV of Amlodipine benzoate, comprising: a. contacting phthaloyl amlodipine with monomethyl amine to obtain Amlodipine free base; b. contacting Amlodipine free base with benzoic acid in a ethyl acetate; and c. isolating crystalline monohydrate Form-IV of Amlodipine benzoate.
In one another aspect, the present invention provides a process for preparing Amlodipine benzoate, comprising: a. contacting phthaloyl amlodipine with monomethyl amine optionally in a solvent to obtain Amlodipine free base; b. contacting Amlodipine free base with benzoic acid in a solvent; and c. isolating Amlodipine benzoate.
Steps (a) and (b), wherein the solvent comprises water, methanol, ethanol, diethyl- ether, methyl tert-butyl ether, 1,4-dioxane, dichlorom ethane, heptane, xylene, toluene or mixture thereof. Preferably, the solvent may be selected from ethanol, methyl tert-butyl ether, toluene or mixture thereof. More preferably, the solvent may be selected from methyl tert-butyl ether, ethyl acetate or toluene.
Step (a) may be carried out at ambient temperatures to 70°C for the time sufficient to obtain Amlodipine free base. Preferably the step (a) may be carried out at the temperature ranging from 20°C to 60°C for the time sufficient to obtain Amlodipine free base. Step (a) may further involve extraction of Amlodipine free base using the organic solvent of step (a) or organic solvent selected from ethyl acetate or dichloromethane followed by optional separation of organic layer from the reaction mixture and washing thereof with brine or water.
Step (a), may further comprise removal of calculated amount of water from the organic layer by either of the methods known to the skilled practitioner, such as distillation, physical adsorption (molecular sieve, anhydrous sodium sulfate, anhydrous magnesium sulfate), chemical water removal or combination thereof. Preferably, the water may be removed by distillation. More preferably, by carrying out azeotropic distillation using dean-stark apparatus.
Step (a) may further comprise isolation of Amlodipine free base from the reaction mixture as solid before contacting the same with benzoic acid. Alternatively, Amlodipine free base is not isolated from the reaction mixture of Step (a) and the reaction mixture is directly contacted with benzoic acid.
Step (b) may be carried out at 0°C to 50°C for the time sufficient to obtain Amlodipine benzoate. Preferably the step (b) may be carried out at 10°C to ambient temperature for the time sufficient to obtain Amlodipine benzoate.
Step (c), wherein Amlodipine benzoate may be isolated by methods such as precipitation, cooling, filtration, centrifugation or combination thereof. The isolated Amlodipine benzoate may optionally be washed with a solvent selected from the group comprising of water, methanol, ethanol, diethyl-ether, methyl tert-butyl ether, ethyl acetate, 1,4-dioxane, dichloromethane, heptane, xylene, toluene or mixture thereof. Thus obtained Amlodipine benzoate is dried by the methods such as vacuum drying, air drying, heat drying, freeze drying or supercritical drying. Any of the mentioned methods may also be used in combination to ensure removal of unbound solvent or water. Preferably Amlodipine benzoate is dried by air, heat and/or vacuum drying methods. A suitable drying temperature is, for example, from 35°C to 100°C, preferably from 40°C to70°C. As may be recognized, the drying time will be dependent upon, amongst other things, the amount of material to be dried, and the particular drying method used. Generally a drying time of 20 minutes to 25 hours, preferably 2 hours to 10 hours is sufficient. Conveniently the drying is performed by heating under vacuum and optionally under inert atmosphere, for example by passing a stream of warm inert gas such as nitrogen over or through material.
In another general aspect, the present invention provides a crystalline form of Amlodipine benzoate having a purity by HPLC of >99%. In particular, a purity by HPLC of >99.5%, more particularly, a purity by HPLC of >99.8%, most particularly, a purity by HPLC of >99.9%.Pharmaceutical Compositions:
Also provided herein is a pharmaceutical composition comprising Amlodipine Benzoate in an amorphous form or crystalline Form 1, Form -II, Form -III, Form- IV or a acceptable hydrate or solvate thereof, as an active pharmaceutical ingredient, in combination with one or more pharmaceutically acceptable carriers or excipients. The choice of excipient, to a large extent, depends on factors, such as the particular mode of administration, the effect of the excipient on the solubility and stability of the active ingredient, and the nature of the dosage form.
The pharmaceutical composition described herein is preferably an Amlodipine Oral Liquid Formulation. The oral liquids pharmaceutical composition may include, but are not limited to, solutions (both aqueous and nonaqueous), suspensions, emulsions, syrups, slurries, juices, elixirs, dispersions, and the like. It is envisioned that solution/suspensions are also included where certain components described herein are in a solution while other components are in a suspension. In some embodiments, the oral liquid formulation is a suspension. INSTRUMENTS
XRPD: X-ray diffraction data is obtained using a Bruker AXS D8 advance (or) equivalent X-ray Diffractometer, CuKa radiation, wavelength 1.54 A.
TGA: TGA measurement is performed using a TGA55; TRIOS software V4.3.1.39215, temperature range 30°C-300°C and 10°C/min. DSC: DSC measurement is performed using DSC25; TRIOS software V4.3.1.39215, temperature range 25°C-300°C and 5°C/min.
KF: KF results is obtained using Metrohm; 870KF Titrino plus. EXAMPLES
Example-1: Process of Crystalline hydrate Form-I of Amlodipine benzoate
Phthaloyl amlodipine (25.0 g, 1 equivalent) was treated with aqueous monomethyl amine solution (Aqueous 40%, 75 ml, 3.0 volumes) at 30°C-50°C in methyl tert-butyl ether (250 ml, 10.0 volume). After completion of reaction, organic layer was separated and aqueous layer back extracted with methyl tert-butyl ether (50 ml X 2 times). Washed the combined methyl tert-butyl ether layer with water (50 ml X 2 times). Distilled out approximately 2.0 volume of methyl tert-butyl ether (50 ml) at atmospheric pressure, cooled the reaction mass to 10°C-30 °C and added methyl tert- butyl ether (75 ml, 3.0 volume) to the reaction mass. Added slowly benzoic acid solution (5.09 g, 0.9 equivalent) dissolved in methyl tert-butyl ether (75 ml, 5.0 volume) at 10°C-30°C. Maintained the reaction mass for 1.0-2.0 hour at 20°C-30°C, filtered the reaction mass and washed with methyl tert-butyl ether (50 ml, 2.0 volume). Dried the product at 50°C-65°C for 8.0 hours in vacuum tray dryer. Output: 21.9 g; yield: 83.42%; HPLC purity: 99.79%; Water content by KF: 6.31% w/w; XRPD peaks: 4.91. 9 78. 10.76. 11.04, 11.43, 12.61, 13.19, 13.69, 14.42, 15 75 16.58, 17.54, 18.50, 19.19 19.74, 20.61, 21.24, 21.57, 22.03 22.96, 23.35, 23.74, 23.96, 24.97 25.59 26.81, 27.02, 27.53, 28.62, 29.59, 30.12, 30.62, 31.16, 31.91, 33.48, 34.45, 34.73, 35.36, 35.98, 36.48, 37.55, 38.94, 39.25, 39.72±0.2°2Q (Fig. 1); TGA: 5.68 weight percentage loss (Fig. 2); DSC: Endotherm with onset temperature 87.24°C (Fig. 3)
Example-la: Process of crystalline dihydrate Form I of Amlodipine benzoate
Phthaloyl amlodipine (301.5 gm, 1 equivalent) was treated with aqueous monomethyl amine solution (Aqueous 40%, 1200 ml, 4.0 volumes) at 30°C-37°C and maintained for 12 hours. Added aqueous monomethyl amine solution (Aqueous 40%, 150 ml, 0.5 volumes) at 30°C-37°C, stirred for 12 and then stirred for 8 hours at 40°C-460 C. After completion of reaction, added water (600 ml, 2 volume) into the reaction mass, stirred the reaction mass at 0°C-10 °C for 2 hours and filtered. The isolated solid was washed with water (1200 ml, 4 volume). The isolated wet solid was partitioned between ethyl acetate (2400 ml, 8 volume) and water (300 ml,
1 volume) followed by layer separation. The ethyl acetate layer was cooled to 0°C -10°C, added water (60 ml, 0.2 volume) and benzoic acid (67.0 gm, 0.98 equivalent) dissolved in the ethyl acetate (600 ml, 2 volume). The wet solid was filtered after 12 hours of maintenance at 0°C -10 °C. The Amlodipine benzoate dihydrate was obtained after drying the wet solid at 30°C -42 °C for 8 hours.
Output- 257 gm, yield-81.43%; HPLC purity: 99.87%.; Water content: 6.36%
XRD: 5.01, 9.87, 10.85, 11.13, 11.56, 12.71, 13.28, 13.71, 14.52, 15.91, 16., 17.63, 18.60, 19.29, 19.84, 20.71, 21.37, 21.66, 22.14, 23.01, 23.49, 24.09, 25.09, 25.70, 26.63, 26.90, 27.13, 27.63, 28.41, 28.72, 29.69, 30.25, 30.70, 31.26, 32.02, 32.67, 33.11, 33.58, 34.02, 34.69, 34.85, 35.47, 36.08, 37.63, 38.01, 38.98.
Example-2: Process of Crystalline Form-II of Amlodipine benzoate Phthaloyl amlodipine (50g, 1.0 equivalent) was treated with aqueous monomethyl amine solution (Aqueous 40%, 200 ml, 4.0 volume) at 30°C -50°C in methyl tert- butyl ether (500ml, 10.0 volume). After completion of reaction, organic layer was separated and aqueous layer back extracted with methyl tert-butyl ether (100 ml X 2 times). Washed the combined methyl tert-butyl ether layer was washed water (100 ml X 2 times). Added methyl tert-butyl ether (100 ml, 2.0 volume) in to the organic layer and filtered through celite bed. Distilled out approximately 2.0 volume of methyl tert-butyl ether (100 ml) at atmospheric pressure and then equipped Dean- Stark apparatus for removal of water azeotropically. After completion of azeotropic distillation, cooled the reaction mass to 10°C -30 °C and added methyl tert-butyl ether (350 ml, 7.0 volume) to the reaction mass. Added slowly benzoic acid solution (10.18 g, 0.9 equivalent) dissolved in methyl tert-butyl ether (250 ml, 5.0 volume) at 10°C -30°C slowly. Maintained the reaction mass for 1.0-2.0 hour at 20°C -30 °C, filtered the reaction mass and washed with methyl tert-butyl ether (50 ml, 2.0 volume). Dried the product at 50°C -65 °C for 8.0 hours in VTD.
Output: 35. Og; yield: 71.06%; HPLC purity: 99.91%; Water content by KF: 0.21% w/w; XRPD peaks: 4.39, 6.02, %A9, 11.14, 11 97. 12.19, 13.43, 14.03, 15.52, 15.27, 15.89, 16.66, 17.07, 17.68, 19.89, 20 50 20 92 22 31 23 03 23 89 24.72, 25.33, 26.24, 26.62, 27.32, 27.75, 28.54, 29.25, 30.14, 32.39, 32.85, 34.02, 35.49 ±0.2° 2Q (Fig. 4); TGA: 0.741 weight percentage loss (Fig. 5); DSC: Endotherm with onset temperature 136.86°C (Fig. 6)
Example-3: Process of crystalline Form-Ill of Amlodipine benzoate
Phthaloyl amlodipine (20g, 1 equivalent) was treated with aqueous monomethyl amine solution (Aqueous 40%, 80 ml, 4.0 volume) at 30°C -50 °C in toluene (100 ml, 5.0 volume). After completion of reaction, organic layer was separated and aqueous layer back extracted with toluene (20 ml X 2 times). Washed the combined toluene layer with water (40 ml X 3 times). Distilled out approximately 1.0 volume of toluene (20 ml) under vacuum below 40°C. Cooled the reaction mass to 10°C -30°C and added toluene (180ml, 9.0 volume) to the reaction mass. Added slowly benzoic acid solution (4.07 g, 0.9 mole eq.) dissolved toluene (100 ml, 5.0 volume) at 10°C -30°C. Maintained the reaction mass for 1.0-2.0 hour at 10°C -30°C, filtered the reaction mass and washed with toluene (20 ml, 1.0 volume). Dried the product at 50°C -65°C for 8.0 hours in VTD.
Output: 16. Og; yield: 81.21%; HPLC purity: 99.79%; Water Content by KF: 0.15% w/w; XRPD peaks: 4.09, 5.60, 7.29, 8.17, 10.47, 11 41 12.17, 12 38 12 83 14.09, 14.65, 15 58 16.29, 16.83, 17.82, 18.27, 18.69, 19.75 20.55, 20.81, 21.17, 21.97, 22.27, 22.64, 23.80 24.08 24.34 25.39, 25.99, 26.52, 27.12, 27.94, 28.26, 29.20, 31.24, 32.24, 33.06, 33.63, 34.52, 35.06, 36.08, 37.74±0.2° 2Q (Fig. 7); TGA: 2.803 weight percentage loss (Fig.8); DSC: Endotherm with onset temperature 125.96°C (Fig. 9).
Example-4: Process of crystalline monohydrate Form IV of Amlodipine benzoate
Phthaloyl amlodipine (151.0 gm, 1 equivalent) was treated with aqueous monomethyl amine solution (Aqueous 40%, 600 ml, 4.0 volumes) at 25°C -35 0 C and maintained for 23 hours. After completion of reaction, added water (300 ml, 2 volume) into the reaction mass and filtered the solid after maintaining the reaction mass at 0°C -10°C for 2 hours. The isolated solid was washed with water (600 ml, 4 volume). The isolated wet solid (20gm equivalent) was dissolved in ethyl acetate (200 ml, 10 volume) and cooled to 0°C -10 °C followed by addition of benzoic acid (4.1 gm, 0.90 equivalent) dissolved in the ethyl acetate (40 ml, 2 volume). The wet solid was isolated after filtration followed by ethyl acetate washing (40 ml, 2 volume). The Amlodipine benzoate monohydrate was obtained after drying the wet solid at 30°C - 42 °C for 8 hours.
Output- 16.1 gm, yield-81.76%; HPLC purity: 99.56%; Water content: 3.33%; XRD peaks: 6.71, 7.93, 11.08, 12.19, 12.46, 12.77, 13.37, 14.32, 15.65, 17.034, 17.08, 18.12, 18.60, 19.13, 19.82, 19.37, 20.06, 21.06, 21.71, 22.20, 22.62, 23.37, 24.00, 24.31, 25.06, 25.85, 26.23, 26.84, 27.44, 27.66, 28.80, 29.31, 29.81, 30.33, 31.32, 32.11, 32.62, 33.69, 35.37, 36.40, 37.65, 38.00, 38.72, 39.26. Example-5: Process for preparation of Amlodipine benzoate amorphous form.
Phthaloyl amlodipine (lOOg, 1.0 equivalent) was treated with aqueous monomethyl amine solution (Aqueous 40%, 400 ml, 4.0 volume) at 30°C -50 °C in methyl tert- butyl ether (1000ml, 10.0 volume) for 8-10 hours. After completion of reaction, organic layer was separated and aqueous layer back extracted with methyl tert-butyl ether (200 ml X 2 times). Washed the combined methyl tert-butyl ether layer was washed water (200 ml X 4 times). Added methyl tert-butyl ether (200 ml, 2.0 volume) in to the organic layer and filtered through Cellite bed. Distilled out approximately 2.0 volume of methyl tert-butyl ether (200 ml) at atmospheric pressure. Take 50g equivalent reaction mass for further experimentation. Cooled the reaction mass to 10°C -30 °C and added methyl tert-butyl ether (350 ml, 7.0 volume) to the reaction mass. Added slowly benzoic acid solution (10.18 g, 0.9 equivalent) dissolved in methyl tert-butyl ether (250 ml, 5.0 volume) at 10°C -30 oC slowly. Maintained the reaction mass for 1.0-2.0 hour at 20-30 °C, filtered the reaction mass and washed with methyl tert-butyl ether (50 ml X 2 times, 2.0 volume). Dried the product at 60°C -65 °C for 8.0 hours in VTD.
Output: 38. Og; yield: 77.14%; HPLC purity: 99.69%; XRPD: Amorphous

Claims

We Claim:
1. A crystalline hydrate of Amlodipine benzoate.
2. The crystalline hydrate of Amlodipine benzoate as claimed in Claim 1 is a crystalline dihydrate Form -I of Amlodipine benzoate characterized by at least one of the following: i. comprising about 6.3% w/w of water; ii. an X-ray powder diffraction (XRPD) pattern comprising peaks at about 4.9, 10.7 and 13.7±0.2° 2Q; iii. an X-ray powder diffraction (XRPD) pattern further comprising peaks at about 9.7, 15.7, 19.2, 22.0, 24.9 and 25.6±0.2° 2Q; or iv. an X-ray powder diffraction (XRPD) pattern substantially the same as depicted in Fig. 1.
3. A process for the preparation of crystalline dihydrate Form-I as claimed in claim 2, of comprising: a) contacting phthaloyl amlodipine with monomethyl amine optionally in methyl tert-butyl ether to obtain Amlodipine free base; b) contacting Amlodipine free base with benzoic acid in methyl tert-butyl ether; and c) isolating crystalline hydrate Form-I of Amlodipine benzoate.
4. The crystalline hydrate of Amlodipine benzoate as claimed in Claim 1 is a crystalline monohydrate Form -IV of Amlodipine benzoate characterized by at least one of the following: i. comprising about 3.33% w/w of water; ii. an X-ray powder diffraction (XRPD) pattern comprising peaks at about 7.93 and 13.37±0.2° 2Q; iii. an X-ray powder diffraction (XRPD) pattern further comprising peaks at about 7.93, 11.08, 12.77, 20.06, 25.85 and 28.8±0.2° 2Q; or iv. a4n X-ray powder diffraction (XRPD) pattern substantially the same as depicted in Fig. 10.
5. A crystalline anhydrous form of Amlodipine benzoate.
6. The crystalline anhydrous form of Amlodipine benzoate as claimed in claim 5, is a crystalline Form-II of Amlodipine benzoate characterized by at least one of the following: i. comprising less thanl% w/w of water; ii. an X-ray powder diffraction (XRPD) pattern comprising peaks at about 4.4, 6.0 and 12.1±0.2° 2Q; iii. an X-ray powder diffraction (XRPD) pattern further comprising peaks at about 8.5, 11.9, 19.9, 20.5, 20.9, 22.3, 23.0 and 23.8±0.2° 2Q; iv. an X-ray powder diffraction (XRPD) pattern substantially the same as depicted in Fig. 4.
7. The crystalline anhydrous form of Amlodipine benzoate as claimed in Claim 5 is crystalline Form-Ill of Amlodipine benzoate characterized by at least one of the following: i. an X-ray powder diffraction (XRPD) pattern comprising peaks at about 4.1 and 5.6±0.2° 2Q; ii. an X-ray powder diffraction (XRPD) pattern further comprising peaks at about 11.4, 12.3, 12.8, 15.5, 19.7, 23.8, 24.0 and 24.3±0.2° 2Q; or iii. an X-ray powder diffraction (XRPD) pattern substantially the same as depicted in Fig. 7.
8. A process for the preparation of Amlodipine benzoate comprising: a) contacting phthaloyl amlodipine with monomethyl amine in a solvent to obtain Amlodipine free base; b) contacting Amlodipine free base with benzoic acid in a solvent; and c) isolating Amlodipine benzoate.
9. An amorphous form of Amlodipine benzoate.
10. A Pharmaceutical composition comprising Amlodipine Benzoate in an amorphous form or crystalline Form 1, Form -II, Form -III, Form -IV or a acceptable hydrate or solvate thereof as claimed in Claims 1-9.
PCT/IN2021/050433 2020-05-06 2021-05-04 Polymorphic forms of amlodipine benzoate and process for the preparation thereof WO2021224942A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202021019251 2020-05-06
IN202021019251 2020-05-06

Publications (1)

Publication Number Publication Date
WO2021224942A1 true WO2021224942A1 (en) 2021-11-11

Family

ID=78467951

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2021/050433 WO2021224942A1 (en) 2020-05-06 2021-05-04 Polymorphic forms of amlodipine benzoate and process for the preparation thereof

Country Status (1)

Country Link
WO (1) WO2021224942A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107445889A (en) * 2017-08-01 2017-12-08 东瑞(南通)医药科技有限公司 A kind of one kettle way prepares Amlodipine Besylate Tablet
US20180098978A1 (en) * 2016-10-07 2018-04-12 Silvergate Pharmaceuticals, Inc. Amlodipine formulations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180098978A1 (en) * 2016-10-07 2018-04-12 Silvergate Pharmaceuticals, Inc. Amlodipine formulations
CN107445889A (en) * 2017-08-01 2017-12-08 东瑞(南通)医药科技有限公司 A kind of one kettle way prepares Amlodipine Besylate Tablet

Similar Documents

Publication Publication Date Title
US8501753B2 (en) Useful pharmaceutical salts of 7-[(3R, 4R)-3-Hydroxy-4-hydroxymethyl-pyrrolidin-1-ylmethyl]-3, 5-dihydro-pyrrolo [3, 2-D] pyrimidin-4-one
KR20180030964A (en) The co-crystals of ibrutinib and carboxylic acid
US11739057B2 (en) Polymorphic forms of Belinostat and processes for preparation thereof
JP6554617B2 (en) Novel crystal form of 1- (5- (2,4-difluorophenyl) -1-((3-fluorophenyl) sulfonyl) -4-methoxy-1H-pyrrol-3-yl) -N-methylmethanamine salt
EP2502917A1 (en) Solid state crystalline forms of 4-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-1H-imidazole
EP2350055A1 (en) Lenalidomide solvates and processes
WO2007109799A2 (en) Polymorphs of eszopiclone malate
WO2008084494A1 (en) Novel polymorphic forms of carvedilol dihydrogen phosphate and process for preparing the same
US20060167265A1 (en) Process for making amlodipine, derivatives thereof, and precursors therefor
JP2002528436A (en) Intermediates for the synthesis of amlodipine, their preparation and use
TW201718516A (en) Crystalline forms of a histone deacetylase inhibitor
EP2975032A1 (en) Crystalline forms of an antidepressant drug
JP2011516519A (en) Polymorph of argatroban monohydrate and its synthesis
CN114437084A (en) Heterocyclic compound and preparation method and application thereof
US9815844B2 (en) Pharmaceutically acceptable salts and polymorphic forms of hydrocodone benzoic acid enol ester and processes for making same
US8344159B2 (en) Carvedilol phosphate sesquihydrate
WO2021224942A1 (en) Polymorphic forms of amlodipine benzoate and process for the preparation thereof
US9458146B2 (en) Crystalline sodium salt of an HIV integrase inhibitor
WO2005023769A1 (en) Process for the preparation of amlodipine salts
EP2072510A1 (en) Crystalline form of azelastine
EP3976598B1 (en) Selective histamine h3 antagonist acid addition salts and process for the preparation thereof
US20220227769A1 (en) Crystalline form of telmapitant or (5r,8s)-8-[[(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]methyl]-8-phenyl-1,3,7-triazaspiro[4.5]decane-2,4-dione
EP4232435A1 (en) Processes for the preparation of ivabradine hcl polymorphs
EP3210975A1 (en) Cocrystals of lorcaserin
JP2021536429A (en) Amorphous and crystalline forms of valbenazine salts

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21799527

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21799527

Country of ref document: EP

Kind code of ref document: A1